oa TAC Protocol in Early Breast Cancer Al Amal Hospital Experience

References

1. Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2008; 58::71–96.
   [Google الباحث العلمي]
2. Berry DA, Cirrincione C, Henderson IC. Estrogen receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295::1658.
   [Google الباحث العلمي]
3.   Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005; 365:9472:1687–1717.
   [Google الباحث العلمي]
4. Eifel P, Axelson JA, Costa J. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer. J Natl Cancer Inst. 2001; 93::979. November 1 -3,2000.
   [Google الباحث العلمي]
5. Cole BE, Gelber RD, Gelber S. Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001; 358::277.
   [Google الباحث العلمي]
6. Montero A, Fossella F, Hortobagyi G. Docetaxel for treatment of solid tumors: A systematic review of clinical data. Lancet Oncol. 2005; 6::229–239.
   [Google الباحث العلمي]
7.   Early Breast Cancer Tria lists' Collaborative Group. Poly chemotherapy for early breast cancer: An overview of the randomizedtrials. Lancet. 1998; 352::930–942.
   [Google الباحث العلمي]
8. Valero V, Holmes F, Walters RS. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline resistant metastatic breast cancer. J Clin Oncol. 1995; 13::2886–2894.
   [Google الباحث العلمي]
9. Ravdin PM, Burris HA III, Cook G. Phase II trial of docetaxel in advance danthracycline-resistant or anthracenedione resistant breast cancer. J Clin Oncol. 1995; 13::2879–2885.
   [Google الباحث العلمي]
10. Chan S, Fried richs K, Noel D. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999; 17::2341–2354.
    [Google الباحث العلمي]
11. Schuller J, Czejka M, Kletzl H. Doxorubicin (DOX) and Taxotere (TXT) a pharmacokinetic (PK) study of the combination in advanced breast cancer. ProcAm Soc Clin Oncol. 1998; 17:205a, Abstract.
    [Google الباحث العلمي]
12. Bellot R, Robert J, Dieras V. Taxotere (T) does not change the pharmacokinetic (PK) profile of doxorubicin (dox) and doxorubicinol (Dx-ol). Proc Am Soc Clin Oncol. 1998; 17:221a, Abstract.
    [Google الباحث العلمي]
13. Gianni L, Munzone E, Capri G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995; 13::2688–2699.
    [Google الباحث العلمي]
14. Gehl J, Boesgaard M, Paaske T. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996; 7::687–693.
    [Google الباحث العلمي]
15. Gianni L, Vigano L, Locatelli A. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997; 15::1906–1915.
    [Google الباحث العلمي]
16. Nabholtz JM, Mackey JR, Smylie M. Phase II study of docetaxel, qdoxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 2001; 19::314–321.
    [Google الباحث العلمي]
17. Nabholtz JM, Falkson C, Campos D. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003; 21::968–975, (Erratum, J Clin Oncol 2003; 21:2048).
    [Google الباحث العلمي]
18. Mackey JR, Paterson A, Dirix LY. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FACas first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). ProcAm Soc Clin Oncol. 2002; 35a:, Abstract.
    [Google الباحث العلمي]
19. Bontenbal M, Braun JJ, Creemers GJ. Phase III study comparing AT (Adriamycin, docetaxel) to FAC (fluorouracil, Adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur J Cancer Suppl. 2003; 1::S201.
    [Google الباحث العلمي]
20. Nabholtz JM, Pienkowski T, Mackey J. Phase III trial comparing TAC (docetaxel, doxorubicin, and cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, and cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. ProcAm Soc Clin Oncol. 2002; 21:36a, Abstract.
    [Google الباحث العلمي]
21. Martin M, Pienkowski T, Mackey J, et al., Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med. 2005; 352::2302–2313.
    [Google الباحث العلمي]
22. Roche H, Fumoleau P, Spielmann M. Sequential adjuvant epirubicinbased and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol. 2006; 24::5664–5671.
    [Google الباحث العلمي]
23. Bria E, Nistico C, Cuppone F. Benefit oftaxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer. 2006; 106:11:2337–2344.
    [Google الباحث العلمي]
24. De Laurentiis M, Cancello G, D'Agostino D. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a metaanalysis of randomized trials. J Clin Oncol. 2008; 26:1:44–53.
    [Google الباحث العلمي]
25. Nabholtz JM, Mackey JR, Smylie M. Phase II study of docetaxel, doxorubicin,and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 2001; 19::314–321.
    [Google الباحث العلمي]